Stockscreener 앱 받기
43.26
0.01%
-0.0277
전일 마감가:
$43.29
열려 있는:
$44.23
하루 거래량:
1.12M
Relative Volume:
0.41
시가총액:
$8.94B
수익:
$2.10B
순이익/손실:
$402.17M
주가수익비율:
22.35
EPS:
1.9357
순현금흐름:
$403.87M
1주 성능:
-0.84%
1개월 성능:
+4.58%
6개월 성능:
-13.08%
1년 성능:
-6.91%
1일 변동 폭
$43.08
$44.32
1주일 범위
$42.57
$44.32
52주 변동 폭
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, NTRA, IDXX, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
43.30 | 9.27B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
605.06 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
209.38 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
321.20 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
544.53 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
150.64 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-03-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-22 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
Qiagen stock trades just below analyst target as latest earnings underpin valuation - Ad-hoc-news.de
Release according to Article 40, Section 1 of the WpHG - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock slips despite Q2 earnings beat and stable guidance - Ad-hoc-news.de
Qiagen stock holds steady as recent earnings support valuation - Ad-hoc-news.de
PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114117 WpHG - TradingView
Qiagen stock advances after topping DAX winners with fresh gain - Ad-hoc-news.de
Qiagen stock holds steady as merger terms clarify for investors - Ad-hoc-news.de
Qiagen NV (QGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
Qiagen NV Annual Shareholders Meeting Transcript - GuruFocus
Qiagen (QGEN) Price Action: Loses 0.66% to Close at $42.32 on the Day; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionQuote Data - vinanet.vn
Qiagen stock steady after Q2 2026 earnings beat and guidance reaffirmation - Ad-hoc-news.de
One Fin Capital Management LP's Qiagen NV(QGEN) Holding History - GuruFocus
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $45.5 to $46.09 - Moomoo
Qiagen stock trades just under analyst targets as Q2 2026 beat supports steady outlook - ad-hoc-news.de
Qiagen stock holds steady after Q2 2026 beat and guidance reaffirmation - ad-hoc-news.de
Qiagen N.V. (QGEN) Stock Analysis: Exploring Its Growth Potential and Strategic Position in Diagnostics - DirectorsTalk Interviews
Handelsbanken Fonder AB Takes $2.91 Million Position in Qiagen N.V. $QGEN - MarketBeat
QIAGEN NV Revenue Breakdown – TRADEGATE:QIA - TradingView
Qiagen stock holds above $43 as Q2 2026 beat backs cautious valuation - ad-hoc-news.de
4% Undervalued? Qiagen (QGEN) As Q2 Beat And FDA Clearance Lift The Story - Yahoo Finance
Qiagen (QGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Qiagen stock holds above $43 as Q2 2026 earnings beat outlook - AD HOC NEWS
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip? - Yahoo Finance
Qiagen stock steadies after Q2 2026 guidance is reaffirmed - AD HOC NEWS
Qiagen stock gains after Q2 beat and fresh FDA clearance - AD HOC NEWS
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen N.V. : DZ Bank reiterates its Buy rating - marketscreener.com
Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing - The Globe and Mail
Qiagen N.V. (QGEN) Latest Stock News & Headlines - Yahoo! Finance Canada
Qiagen Sees Unusually High Options Volume (NYSE:QGEN) - MarketBeat
Goldman Sachs lifts Qiagen voting rights to 2.63% via instruments - Bitget
Qiagen NV (QGEN) Shares Surge 3.7% -- What GF Score of 76 Tells Investors - GuruFocus
New QIAGEN Test Detects 20 Pathogen Targets in About an Hour - Stock Titan
QGEN Maintained by Citigroup -- Price Target Raised to $45.00 - GuruFocus
QIAGEN Wins FDA Clearance for a One-Hour Bloodstream Infection Test, With Montgomery County Ties Behind It - BioBuzz
Understanding Qiagen (QGEN) Reliance on International Revenue - Yahoo Finance
Qiagen N.V. (QGEN) Investor Outlook: Analyzing Growth Potential With An 8.24% Upside - DirectorsTalk Interviews
Qiagen N.V. : Deutsche Bank remains its Buy rating - marketscreener.com
63,219 Shares in Qiagen N.V. $QGEN Bought by The Manufacturers Life Insurance Company - marketbeat.com
Qiagen Q2 Earnings Call Highlights - MarketBeat
QIAGEN Beats Q2 2026 Guidance, Reaffirms Full-Year Outlook Amid Mixed Demand - The Globe and Mail
William Blair Maintains Qiagen NV(QGEN.US) With Hold Rating - 富途牛牛
How Investors Are Reacting To Qiagen (QGEN) Capital Structure Overhaul And US$200 Million Repayment Plan - Sahm
Qiagen NV (QGEN) Stock News Today - TradingKey
Qiagen N.V. Stock 12‑Month Price Target Raised to $44.52, Implies 7% Upside - TradingView
QGEN Maintained by Barclays -- Price Target Raised to $40 - GuruFocus
Qiagen NV (QIA.SG) stock price, news, quote and history - Yahoo Finance UK
QGEN Maintained by JP Morgan -- Price Target Raised to $50 - GuruFocus
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
자본화:
|
볼륨(24시간):